Royalty Pharma plc Class A Ordinary Shares vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.52 (market cap $299.40M). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 84.4× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| RPRX | YMAG | |
|---|---|---|
Market Cap | $25.27B | $299.40M |
Volume | 3,671,183 | 843,109 |
Sector | Health | Income / Options Overlay |
52-Week High | $63.96 | $15.68 |
52-Week Low | $35.44 | $10.76 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →